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Background: The system L amino acid transporter (LAT) has an important role in the transport of various amino
acids, and there have been reports about the relation of this system to cancer. Although LATs are highly expressed
in the kidneys, little is known about their influence on human renal cancer.
Methods: To clarify the role of LATs in human clear cell renal cell carcinoma (RCC), we investigated the expression
of mRNAs for LAT1, LAT2, LAT3, LAT4, and 4F2hc in clear cell RCC tissues. The mRNAs of these five genes were
analyzed by the real-time reverse transcription polymerase chain reaction in matched sets of tumor and non-tumor
tissues obtained at operation from 82 Japanese patients with clear cell RCC. We also measured phosphorylated S6
ribosomal protein (Ser-235/236) proteins levels in 18 paired tumor and non-tumor tissues of the patients by
Western blotting.
Results: Expression of LAT1 mRNA was significantly increased in tumor tissue compared with non-tumor tissue,
while expression of LAT2 and LAT3 mRNAs was reduced. There was no difference in the expression of LAT4 and
4F2hc mRNAs between tumor and non-tumor tissues. Increased expression of LAT1 mRNA was associated with less
differentiated tumors, local invasion, microscopic vascular invasion, and metastasis. Kaplan-Meier survival analysis
showed that a higher serum LAT1 mRNA level was associated with a shorter overall survival time. Phosphorylated
S6 ribosomal protein levels were associated with metastatic potential. LAT1 mRNA levels positively correlated with
phosphorylated S6 ribosomal protein proteins levels in primary tumors.
Conclusions: These findings suggest that LAT1 mRNA is related to the invasive and progressive potential of clear
cell RCC.Background
Renal cell carcinoma (RCC) is a common tumor that ac-
counts for about 3% of all adult malignancies [1]. Local-
ized RCC is generally considered to be suitable for
surgical resection, but almost 30% of the patients with
limited disease at the time of surgery develop metastasis* Correspondence: kamait@dokkyomed.ac.jp
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reproduction in any medium, provided the orwithin the next 3 years [2]. Furthermore, clear cell RCC
is a highly vascular tumor, so many patients already have
metastasis at the time of diagnosis [1]. Metastasis occurs
when cancer cells spread from the primary tumor to dis-
tant sites [3], and is the major cause of cancer death.
RCC patients with distant metastases have a poor prog-
nosis and their 5-year survival rate is less than 10% [2].
Tumor cells require a steady and adequate supply of
sugars and amino acids to maintain metabolism and protein
synthesis at a high enough level for rapid growth and prolif-
eration [4,5]. Aminoacid transporters are essential for theral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Data collection of patient and tumor characteristics
Patient
No. of patients 82
Age (yrs) 63.1 (39–83)
Sex (male / female) 62 / 20
follow-up times (months) 46 (3–112)
Tumor
Histological grading (G1 /G 2 / G3 / G4) 17 / 41 / 24 / 0
pT stage (T1 / T2 / T3 / T4) 34 / 16 / 30 / 2
Microscopic vascular invasion (v0 / v1) 49 / 33
Metastasis (M0 / M1) 60 / 22
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formed cells [6,7]. The increased requirement of tumor cells
for nutrients may be met by increasing the supply through
vasculogenesis and by enhanced cellular uptake through
upregulation of specific transporters [8]. The system large
amino acid transporter (LAT) is a major nutrient transport
system that is responsible for Na+-independent transport of
large neutral amino acids [9,10]. It plays a critical role in
the absorption of amino acids from the small intestine, as
well as in movement of amino acids across the blood–brain
barrier, the placenta, and the proximal tubules of the kid-
neys [6,7]. Interestingly, LAT1 is associated with cancerous
or proliferative cells, and it has been reported that LAT1 is
highly expressed in proliferating tissues, many tumor cell
lines, and primary human tumors [10-16]. Thus, LAT1 may
play a key role in the growth of tumor cells by promoting
the uptake of essential amino acids. Indeed, the LAT1-
specific inhibitor JPH203 (KYT0353) was reported to re-
duce the incorporation of essential amino acids by cancer
cell lines and to attenuate the growth of human tumor cells
implanted into nude mice [17], indicating that LAT1 might
be an attractive target for cancer therapy.
After LAT1 was isolated by expression cloning, it was
found to be co-expressed with the heavy chain of 4 F2
cell surface antigen (4F2hc) and to be involved in the
transportation of neutral amino acids [9]. Three other
LAT isoforms (LAT2, LAT3, and LAT4) have been iden-
tified in addition to LAT1 and together these four iso-
forms comprise the system L amino acid transporter
[18-20]. The mRNAs of LAT2 and 4F2hc are ubiquitously
expressed in normal tissues, including the glomerular par-
ietal epithelial cells and podocytes in the kidney, and co-
expression of LAT2 with 4F2hc promotes amino acid
uptake as does the LAT1/4F2hc complex [18,21]. In
addition, LAT3 has been localized to glomerular podo-
cytes [22], while LAT4 is expressed in several organs such
as the brain, intestine, placenta, and kidney [20]. In the
kidney, LAT4 is found in the distal tubules and collecting
ducts [20]. Thus, LATs 1–4 and 4F2hs seem to have an
important influence on normal kidney function, but the
expression and role of these proteins in human RCC re-
main unclear. Accordingly, this study was performed to
investigate the expression of mRNAs for the four LATs
(LAT1, LAT2, LAT3, and LAT4) and 4F2hc in RCC pa-
tients, and to compare the findings with clinicopathological
data. It was hoped that the information thus obtained
would shed light on the role of LATs in cancer progression.
Methods
Patients and samples
We studied 82 Japanese patients (62 men and 20 women)
aged from 39 to 83 years (mean age: 63.1 years) who had
newly diagnosed clear cell RCC (without sarcomatoid or
rhabdoid components) from 1999 to 2012. All patientsunderwent CT and/or MRI for preoperative staging prior to
radical nephrectomy. The postoperative follow-up period
ranged from 3 to 112 months (median: 46 months). Surgery
was performed before any other therapy. Patient and tumor
characteristics are summarized in Table 1. In order to take
into account possible inter-individual variation in the ex-
pression of LAT family (LAT1, LAT2, LAT3, LAT4, and
4F2hc) mRNAs and phosphorylated S6 ribosomal protein
(Ser-235/236), tumor tissue samples and the corresponding
non-tumor tissue samples obtained from the same patient
were compared. The non-tumor control tissues were appar-
ently free of RCC and were obtained from as distant a site
as possible. If the tumor was located in the central part
(middle portion) of the kidney, non-tumor tissues were ex-
tracted from the upper or lower pole. If the tumor was lo-
cated in the upper or lower pole, non-tumor tissues were
extracted from the opposite pole. The resected tissues were
stored at -80°C, as described previously [23,24]. The tumor
grade and clinical stage were determined according to the
Fuhrman grading system and the TNM classification, re-
spectively [25,26]. In the present study, all of the tumors
were histological grades 1 to 3. Histopathological examin-
ation of the resected kidneys was performed independently
by two pathologists. If abnormalities were later detected in
the putatively normal tissue sample, the patient was ex-
cluded from the study. This study was conducted in ac-
cordance with the Helsinki Declaration and was approved
by the Dokkyo Medical University Hospital institutional
ethical review board. In addition, each patient signed a con-
sent form that was approved by our institutional Commit-
tee on Human Rights in Research.
Postoperative adjuvant therapy with interferon (IFN)-
alpha (3, 5, or 6 million units of natural human IFN-alpha
two or three times a week), sorafenib (400 or 800 mg/
day), or sunitinib (25 to 50 mg/day for 4 weeks, followed
by two weeks of rest) was usually administered to patients
with extra-renal involvement (metastatic disease) until
progression occurred. The doses of these agents were de-
creased if grade 3/4 toxicity occurred.
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reaction assay
Total RNA was purified from all 82 sets of tumor and
non-tumor tissue samples with an RNA preparation kit
(“High Pure RNA Kit”; Roche Diagnostic Ltd., Germany),
and was used as a template for the synthesis of cDNA.
The reaction mixture (100 μL) contained 1 μg of random
hexamers and 100 units of MMLV-reverse transcriptase,
with incubation being done at 25°C for 10 min, 42°C for
30 min, and then at 99°C for 5 min in a TP960 Thermal
Cycler Dice (Takara Bio Ltd., Shiga, Japan) with SYBR
Green. The following primers were used to amplify the in-
dicated genes in tumor tissues after confirming their spe-
cificity (Takara Bio Ltd., Shiga, Japan)):
LAT1, sense; 5′- GCATCGGCTTCACCATCATC -3′,
anti-sense; 5′- ACCACCTGCATGAGCTTCTGAC -3′;
LAT2, sense; 5′- TTTGCCTATGGAGGCTGGAAC -3′,
anti-sense; 5′- GCGACATTGGCAAAGACATACAC -3′;
LAT3, sense; 5′- ATGGACTGGCGGATCAAGG -3′,
anti-sense; 5′- TCTTGCAGTAGCGTGGTCTGATG -3′;








β-actin, sense; 5′- CTGGCATCGTGATGGACTC
CGG -3′,
anti-sense; 5′- GTGGATGCCACAGGACTCCATG-3′,.
Real-time RT-PCR was performed in a 25 μL reaction
mixture containing 20 ng of sample cDNA, 100 nM
sense primer, 100 nM anti-sense primer, and 12.5 μL of
SYBR Green PCR Master Mix (Applied Biosystems).
PCR was carried out with 45 cycles of 95°C for 15 sec
and 60°C for 1 min. Then the products were normalized
for β-actin as an internal control [14,15]. A standard
curve was generated for each mRNA by five-fold dilu-
tion of a control RNA sample (25×, 5×, 1×, 0.2×, and
0.04×), and the expression of each target mRNA was cal-
culated as a ratio to that of β-actin to determine the
relative level of expression [23,24]. The mean value ob-
tained by analyzing three samples of resected tissue was
calculated as described previously [24].
Western blotting
We could only perform Western blotting for 18 tumors.
Samples of tumor tissue and normal tissue were care-
fully dissected free of stromal tissue. Western blotting
for phosphorylated S6 ribosomal protein (Ser-235/236)
was carried out as described previously [27,28]. In brief,10 μg of cytosolic protein was separated by SDS-PAGE
(4-12% gel), electrotransfer to a polyvinylidene difluoride
membrane (iBlot Gel Transfer Stacks PVDF, Mini; Life
Technologies, Carlsbad, CA) was performed. After the
membrane was blocked, the bound proteins were probed
with an anti-phosphorylated S6 ribosomal protein (Ser-
235/236) antibody, 2 F9, which is an anti-human primary
antibody and was raised in rabbits (Cell Signaling Tech-
nology, Inc; # 4856), and a primary antibody for β-actin
(Millipore; # 1501R Bedford, MA). Hela cells were used
as the positive control. Next, the membranes were washed
and incubated with horseradish peroxidase-conjugated sec-
ondary antibodies. Bands of antibody-bound proteins were
visualized by chemiluminescence, the blotted membrane
was scanned for densitometry with a PDI imaging scanner
(Agfa Japan, Tokyo), and the data were analyzed with NIH
Image software (ImageJ for Mac OS, version 1.47). Expres-
sion of phosphorylated S6 ribosomal protein (Ser-235/236)
was calculated relative to that of β-actin in the tumor tissue
specimens and corresponding normal tissue specimens.
For quantification of these proteins, the relative amount
of phosphorylated S6 ribosomal protein (Ser-235/236) in
tumor tissue was expressed as a ratio of the optical density
of the band for the tumor tissue specimen to that for the
corresponding normal tissue specimen (set at 1.0) by
densitometric analysis, as described previously [27,28]. The
mean values for specimens of tumor and non-tumor tissue
were calculated from three experiments [27,28].
Statistical analysis
Comparison between groups was performed by the
Mann–Whitney U-test for two groups (pT stage,
microscopic vascular invasion, and metastasis) or the
Kruskal-Wallis test for three groups (tumor histological
grade), as described previously [13-15]. Spearman’s rank
correlation coefficient analysis was employed to determine
the relation between LAT1 mRNA and phosphorylated S6
ribosomal protein (Ser-235/236) expression. LAT mRNA
expression, tumor grade, pT stage, microscopic vascular in-
vasion, and metastasis were assessed for their impact on
survival by Cox proportional hazards analysis using univari-
ate and multivariate models. The Kaplan-Meier method
was employed to estimate survival, for various groups, and
differences between the groups were assessed by the log-
rank test. In all analyses, a probability (P) value of less than
0.05 was considered to indicate significance. Data were ana-
lyzed with commercially available software.
Results
LATs mRNAs expression and tumor characteristics
Although the expression of LAT1 mRNA was increased
in tumor tissue (mean ± S.D. = 1.78 ± 3.95) compared
with non-tumor tissue (0.42 ± 1.36, P < 0.0001, Figure 1A),
expression of LAT2 and LAT3 mRNAs was decreased in
Figure 2 LAT1 mRNAs in tumors. a; grade. b; pT stage. c; microscopic vascular invasion. d; metastasis. The data show the 95% confidential interval.
Figure 1 LATs mRNA expressions between tumor and non-tumor tissues in human clear cell renal cell carcinoma. a; LAT1, b; LAT2, c;
LAT3, d; LAT4, e; 4F2hc. The data show the 95% confidential interval.
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Table 2 Quantitative PCR measurements of LATs mRNAs and pS6K protein densitometry results
Real time RT-PCR for mRNAs Western blotting for pS6K protein
LAT1 LAT2 LAT3 LAT4 4h2Fc Number = 18
Number = 82 P value P value P value P value P value Number = 18
Tissue










n = 18 3.03 ± 1.91
3.03 ± 1.91
non-tumor n = 82 0.42 ± 1.36 0.74 ± 0.76 0.69 ± 0.55 0.87 ± 0.53 0.81 ± 0.85 n = 18 1.27 ± 0.37
Grade
G1 n = 17 1.56 ± 2.33
0.0023






n = 3 3.84 ± 2.25
0.3596G2 n = 41 1.36 ± 4.61 0.07 ± 0.07 0.9112 0.35 ± 0.36 0.90 ± 0.59 0.55 ± 0.38 n = 9 2.63 ± 1.66
G3 n = 24 2.75 ± 3.18 0.34 ± 1.32 0.30 ± 0.20 0.55 ± 0.36 0.54 ± 0.43 n = 6 4.27 ± 1.99










n = 10 2.48 ± 1.12
0.0849














n = 10 2.77 ± 1.12
0.2087
v1 n = 33 3.11 ± 5.70 0.27 ± 1.13 0.35 ± 0.26 0.78 ± 0.57 0.55 ± 0.39 n = 8 3.66 ± 2.33
Metastasis










n = 9 2.11 ± 1.24
0.0083
M1 n = 22 2.02 ± 2.69 0.17 ± 0.84 0.32 ± 0.33 0.78 ± 0.53 0.55 ± 0.42 n = 9 3.84 ± 2.05
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Figure 1B, and 0.32 ± 0.31 versus 0.69 ± 0.55, P <
0.0001, Figure 1C, respectively). In contrast, there were
no differences of LAT4 and 4F2hc mRNA expression
between tumor and non-tumor tissues (LAT4: 0.79 ±
0.53 versus 0.87 ± 0.53, P = 0.2199, Figure 1D; 4F2hc:
0.55 ± 0.39 versus 0.81 ± 0.85, P = 0.1496, Figure 1E).
Increased expression of LAT1 mRNA in primary renal
tumors was related to the poorer differentiation (Figure 2A,
Table 2). Expression in primary renal tumors was not re-
lated to the histological grade in the case of LAT2 mRNA,
LAT3 mRNA, and LAT4 mRNA as well as 4F2hc mRNA
(Table 2).
A higher level of LAT1 mRNA expression in the pri-
mary tumor was associated with local invasion (Figure 2B,
Table 2). Expression of LAT2 and LAT3 mRNAs was
lower in tumor tissue than in non-tumor tissue, and nei-
ther LAT2 nor LAT3 was associated with local invasion
(Table 2). Expression of LAT4 and 4F2hc mRNAs in
the primary tumor was also unrelated to the pT stage
(Table 2).
Higher expression of LAT1 mRNA in the primary
tumor was associated with microscopic vascular invasion
(Figure 2C, Table 2). In contrast, expression of the other
LAT mRNAs showed no difference between v1 and v0
tumors (Table 2).
Investigation of the association with metastasis showed
that the level of LAT1 mRNA expression in primary
tumor tissues differed significantly between RCC with
metastasis (M1) or without metastasis (M0) (Figure 2D,
Table 2). In contrast, there was no difference in the ex-
pression of LAT2, LAT3, or LAT4 mRNAs, as well as
4F2hc mRNA (Table 2).
Relationship between LAT mRNA and phosphorylated S6
ribosomal protein (Ser-235/236)
Western blotting of 18 resected kidney specimen showed
that the expression of phosphorylated S6 ribosomal protein
(Ser-235/236) was higher in primary tumors than in nor-
mal tissues (Figure 3, Table 2), and its increased expression
was associated with metastasis, but not grade, pT stage,
and vascular invasion (Figure 4, Table 2). We investigated
the correlation between LAT1 mRNA and phosphorylatedFigure 3 Expression of phosphorylated S6 ribosomal protein
(Ser-235/236) (32 kDa) and beta actin (42 kDa) proteins in the
primary tumor tissues using Western blotting. M; marker. N;
non-tumor tissue. T; primary tumor tissue with metastatic lesions.
Each number corresponds to a case number.S6 ribosomal protein (Ser-235/236) expression in 18 tumor
tissues. When LAT1 was used as an independent variable
and phosphorylated S6 ribosomal protein (Ser-235/236) as
a dependent variable, a positive correlation between them
was observed (r2 = 0.508, P = 0.0009, Figure 5).
LATs mRNAs expression and survival
The median level of L expression in tumor tissues was
0.52, so the patients were divided into two groups at this
cut-off value to give a high-expression group (n = 41)
and a low-expression group (n = 41). Kaplan-Meier plots
of survival for the high-expression and low-expression
groups showed that increased expression of LAT1 mRNA
was associated with shorter overall survival (P = 0.0008,
Figure 6A). In contrast, on the similar criteria as well as
LAT1, the levels of the other LAT mRNAs were not re-
lated to overall survival (Figures 6B-E).
Univariate analysis of overall survival was performed
with the Cox proportional hazards model and it revealed
that histological grade, pT stage, microscopic vascular
invasion, metastasis, and LAT1 mRNA expression were
all significant determinants of survival. On multivariate
analysis, metastasis was identified as an independent fac-
tor (P = 0.0172) for survival and pT stage showed a weak
association (P = 0.0616) (Table 3).
Discussion and conclusions
To the best of our knowledge, this is the first investigation
of the relation between the expression of LAT mRNAs
(LAT1, LAT2, LAT3, and LAT4) or 4h2hc mRNA and the
clinicopathologic features of clear cell RCC. To allow for
possible inter-individual variation in the expression of
LAT mRNAs, we performed comparison of mRNA ex-
pression between paired samples of tumor and non-tumor
tissues from the same kidney. This revealed that LAT1
mRNA expression was higher in tumor tissue than in
non-tumor tissue. In addition, the LAT1 mRNA level was
significantly higher in less differentiated primary tumors
(grade 3), as well as tumors with local invasion (pT3-4),
microscopic vascular invasion (v1), and metastasis (M1),
than in tumors without these features. Furthermore, in-
creased expression of LAT1 mRNA in the primary tumor
was correlated with an unfavorable prognosis. These find-
ings suggest that LAT1 may have an influence on the inva-
sive potential and progression of clear cell RCC.
The primary features of the malignant phenotype are
maintained via intrinsic modification of metabolic activ-
ity, which is characterized by enhancement of the nutri-
ent supply, energy production, and synthesis of a variety
of macromolecular components. This metabolic shift in
transformed cells, as compared with non-proliferating
cells, involves aberrant activation of aerobic glycolysis,
de novo lipid biosynthesis, and glutamine-dependent
anaplerosis to fuel rapid cell growth and proliferation.
Figure 5 Spearman rank correlation coefficient relationship.
X axis is an independent variable. Y axis is a dependent variable.
LAT1 mRNA levels positively correlated with phosphorylated S6
ribosomal protein (Ser-235/236) levels in primary tumor tissues.
Figure 4 Expression of phosphorylated S6 ribosomal protein (Ser-235/236). a; tumor. b; grade. c; pT stage. d; microscopic vascular invasion.
e; metastasis. The data show the 95% confidential interval.
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to glycolysis (the Warburg effect) is one of the typical
strategies employed for the generation of ATP by cancer
cells [29]. Because tumor cells have an increased re-
quirement for nutrients, this is met by increasing nutri-
ent availability through vasculogenesis and by enhanced
cellular uptake of nutrients through upregulation of spe-
cific transporters [8]. Given this well-established influ-
ence of energy metabolism on tumor development and
growth, reprogramming of energy metabolism can be
viewed as one of the “Hallmarks of Cancer” [30].
Amino acids are essential for protein synthesis, and
thus are required for the growth and proliferation of
both normal and transformed cells. Amino acid trans-
port across the plasma membrane is mediated by various
amino acid transporters that are localized to the membrane
[6,7]. Among them, LAT is a major nutrient transport sys-
tem that contributes to the growth and proliferation of
both normal and transformed cells [6,31]. LAT is also es-
sential for amino acid transport in the proximal tubules of
the kidneys [6,7], and clear cell RCC has been suggested to
arise from the proximal tubules [32].
LAT1 was the first LAT isoform to be isolated, and it
has been reported that LAT1 is overexpressed in primary
human neoplasms and involved in tumor cell proliferation
due to its role in the transport of essential amino acids
[10,33]. There is evidence that increased LAT1 expressionis associated with a poor prognosis of various cancers, in-
cluding brain tumors [11], lung cancer [12], gastric cancer
[13], urothelial cancer [14], and prostatic cancer [15]. Fur-
thermore, it has been reported that LAT1 not only pro-
vides cancer cells with amino acids required for protein
synthesis but also with amino acids that stimulate cell
growth via mammalian targeting of rapamycin (mTOR)
[31], and that the amino acid supply is coupled to cell
Figure 6 Survival curve based on the median values of mRNA expression of LATs in tumors, the cases were divided into two groups at
this levels high and low expression. a; LAT1, b; LAT2, c; LAT3, d; LAT4, e; 4F2hc.
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both cell growth and cell cycle progression [34,35]. Wang
et al. recently reported that prostate cancer cells regulate




No. of patients Anal
Univaria
Grade 3 / 2 / 1 21 / 33 / 17
Multivari
U
pT 4,3 / 2,1 43 / 28
M
U
v (+) / (−) 43 / 28
M
U
M (+) / (−) 18 / 53
M
U
LAT1 high / low 41 / 41
Mfor mTOR complex 1 (mTORC1) signaling and cell
growth, while inhibiting LAT function led to decreased
growth and mTORC1 signaling in these cells [36]. Thus,
mTORC1 controls cell growth by regulating proteintic factors in survival
n all patients
ysis Relative risk 95% confidential interval P value
te (U) 6.080 2.799 - 13.209 < 0.0001
ate (M) 1.693 0.838 - 3.424 0.1424
41.532 5.598 - 308.114 < 0.0001
9.21 0.897 - 94.539 0.0616
9.981 3.407 - 29.245 < 0.0001
1.548 0.423 - 5.674 0.5093
12.098 4.927 - 29.709 < 0.0001
3.222 1.231 - 8.434 0.0172
4.625 1.724 - 12.407 0.0023
1.977 0.635 - 6.150 0.2393
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inhibitors are currently under investigation for the treat-
ment of various human cancers. mTORC1 lies down-
stream of PI3K/Akt pathway and this pathway is frequently
activated in human clear cell RCCs [28], so mTORC1 rep-
resents a pivotal target for anticancer therapy in RCCs
[37-39]. In our previous report, phosphorylated S6 riboso-
mal protein (Ser-235/236), the best-characterized down-
stream effector of mTORC1, was upregulated in the
primary tumors with metastatic phenotype [28]. In the
present study, the tumor tissue levels of LAT1 mRNA and
phosphorylated S6 ribosomal protein (Ser-235/236) were
positively correlated, and higher expression level of LAT1
mRNA and phosphorylated S6 ribosomal protein (Ser-235/
236) was associated with metastatic potential. Taken to-
gether with these reports, our findings suggest that LAT1
and phosphorylated S6 ribosomal protein (Ser-235/236)
may cooperatively influence the invasive potential and
progression of RCC.
On the other hand, how the LATs are associated with
cancer has not been fully elucidated from the molecular
biological perspective. Hayashi et al. recently reported
that c-Myc is crucial for the expression of LAT1, and
LAT1 is a central transporter of essential neutral amino
acids in human pancreatic cancer cells [40]. c-Myc is a
proto-oncogene that encodes a transcription factor, and
it is known to enhance biosynthesis as well as energy
generation, with genes involved in glucose transport and
the glycotic pathway being upregulated by c-Myc [41,42].
Recently, closer attention has been paid to the role of Myc
in cancer cell metabolism for cancer treatment [43,44].
On the other hand, several studies have shown that the c-
Myc pathway is activated in RCC due to overexpression
and amplification of the c-Myc gene. [45,46]. Thus, c-Myc
might play a role in tumorigenesis by regulating the ex-
pression of genes involved in metabolism that are required
for cell proliferation and development of the malignant
phenotype.
In the present study, RCC showed lower expression of
LAT2 and LAT3 mRNAs in comparison with non-tumor
renal tissue. In contrast, there were no differences in the
expression of LAT4 and 4F2hc mRNAs. Luo et al. re-
ported that the level of LAT2 mRNA, but not 4F2hc
mRNA, was significantly higher in leiomyoma tissue com-
pared with matched myometrial tissue, and that small
interfering RNA knockdown of LAT2 or 4F2hc markedly
increased the growth of primary human uterine leiomyoma
smooth muscle cells, indicating that LAT2/4F2hc may play
an important role in leiomyoma cell proliferation [47].
Kaira et al. recently reported that 4F2hc expression in-
creased from a low to high histological grade and was sig-
nificantly associated with worse overall survival in patients
with pulmonary neuroendocrine tumors [48]. 4F2hc has
been reported to be involved in cellular proliferation,transformation, fusion, and adhesion, and it also contrib-
utes to the LAT system. In addition, 4F2hc is involved in
regulating integrin activation, and therefore has a role in
integrin signaling and anchorage-independent growth.
4F2hc is reconstituted and expressed at high levels on the
surface of many types of tumor cells. Recent studies have
demonstrated that 4F2hc expression is increased in a var-
iety of cancers and has a crucial role in the progression
and metastasis of human neoplasms [49-51]. In contrast to
the above, there have been few reports about the expres-
sion of LAT3 and LAT4 mRNAs in human cancer.
The present study revealed that increased LAT1 mRNA
expression is associated with invasion of RCC and an un-
favorable prognosis, suggesting a potential role of LAT1
upregulation in the progression of human cancer and the
possibility of using LAT1 mRNA as a target for anticancer
treatment. However, our study included a relatively small
number of patients and the follow-up period was too short
to draw definite conclusions regarding the possible rela-
tions between LAT mRNAs and the prognosis of RCC.
Moreover, it is important to study the relationship be-
tween expression of LAT mRNAs and the efficacy of IFN-
alpha, sorafenib, and sunitinib. Furthermore, we should
investigate the molecules transported by LATs that are
key players in carcinogenesis and cancer progression in
order to fully elucidate the molecular mechanisms by
which LATs participate in human diseases including can-
cer. Such information may shed light on the LAT mRNAs
that are useful biomarkers.
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